Tag: crossover

Neue Studie liefert Erkenntnisse über die Bioverfügbarkeit von medizinischen Cannabisformulierungen für therapeutische Behandlungen

Hangzhou, China, June 24, 2025 (GLOBE NEWSWIRE) --

As smart advances through 2025 - the year of enhancing global operation – the premium electric automotive brand continues to drive innovation across global markets through strategic partnerships and product excellence. In the first half of 2025, smart has made significant inroads into the global market landscape, successfully entering seven new markets across the MENA region and Latin America. The business footprint has now expanded to 38 countries and regions, with exceeding 580 stores worldwide. 

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.